Immunohistochemical expression of 14-3-3 sigma protein in various histological subtypes of uterine cervical cancers

Pathology International

Volumn 54, Issue 10, 2004, Pages 743-750

  Sano, Takaaki ^a,b   Shimooka, Hanako ^a   Weixa, Peng ^a   Segawa, Atsuki ^a   Jian, Zhang ^a   Motegi, Atsushi ^a   Nakayama, Hiroko ^a   Oyama, Tetsunari ^a   Nakajima, Takashi ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

14 3 3 ; Adenocarcinoma; Immunohistochemistry; p16; Squamous cell carcinoma; Uterine cervix

Indexed keywords

MESSENGER RNA; PROTEIN 14 3 3; PROTEIN P16; PROTEIN P53; VIRUS DNA;

ADENOCARCINOMA; ARTICLE; CANCER DIAGNOSIS; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; VIRUS TYPING; WART VIRUS;

ADENOCARCINOMA; CARCINOMA; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EXONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS;

EID: 7544241578     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2004.01747.x     Document Type: Article

References (36)

1. Prasad GL, Valverius EM, McDuffie E, Cooper HL. Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. Cell Growth Differ 1992; 3: 507-13.
2. Hermeking H, Lengauer C, Polyak K et al. 14-3-3 sigma is a p53-regulated inhibition of G2/M progression. Mol Cell 1997; 1: 3-11.
3. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401: 616-20.
4. Conklin DS, Galaktionov K, Beach D. 14-3-3 proteins associate with cdc25 phosphatases. Proc Natl Acad Sci USA 1995; 92: 7892-6.
5. Laronga C, Yang HY, Neal C, Lee MH. Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 2000; 275: 23 106-12.
6. Ferguson AT, Evron E, Umbricht CB et al. High frequency of hypermethylation at the 14-3-3σ locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000; 97: 6049-54.
7. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Markes J, Sukumar S. Hypermethylation of 14-3-3σ (stratifin) is an early event in breast cancer. Oncogene 2001; 20: 3348-53.
8. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K. Inactivation of the 14-3-3σ gene is associated with 5′-CpG island hypermethylation in human cancers. Cancer Res 2000; 60: 4353-7.
9. Iwata N, Yamamoto H, Sasaki S et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3σ gene in human hepatocellular carcinoma. Oncogene 2000; 19: 5298-302.
10. INK4a silencing and human papillomavirus negativity. Cancer Res 2002; 62: 2072-6.
11. INK4a is an early event in vulval squamous neoplasia. Oncogene 2002; 21: 1876-81.
12. Urano T, Saito T, Tsukui T et al. Efp targets 14-3-3σ for proteolysis and promotes breast tumor growth. Nature 2002; 417: 871-5.
13. Nakajima T, Shimooka H, Weixa P et al. Immunohistochemical demonstration of 14-3-3 sigma protein in normal human tissues and lung cancers, and the preponderance of its strong expression in epithelial cells of squamous cell lineage. Pathol Int 2003; 53: 353-60.
14. zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1996; 1288: F55-78.
15. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-9.
16. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16, E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-7.
17. Choo K-B, Chang KY. Absence of mutation in the p53 and the retinoblastoma genes in primary cervical carcinomas. Virology 1993; 193: 1042-6.
18. Kelley MJ, Otterson GA, Kaye FJ, Popescue NC, Johnson BE, Dipaolo JA. CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines. Int J Cancer 1995; 63: 226-30.
19. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153: 1741-8.
20. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H, Iwamoto A. Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res 1991; 82: 524-31.
21. Sakurai S, Sano T, Maeshima A et al. Gastric adenoma-carcinoma sequence with special reference to p53 and Ki-ras gene alterations. Virchows Arch 1995; 427: 119-24.
22. Xue Q, Sano T, Kashiwabara K, Oyama T, Nakajima T. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in squamous cell carcinomas of lung. Jpn J Cancer Res 2001; 92: 285-92.
23. Osada H, Tatematsu Y, Yatabe Y et al. Frequent and histological type-specific inactivation of 14-3-3σ in human lung cancers. Oncogene 2002; 21: 2418-24.
24. Leffers H, Madsen P, Rasmussen HH et al. Molecular cloning and expression of the transformation sensitive epithelial marker stratiffin. A member of a protein family that has been involved in the protein kinase C signaling pathway. J Mol Biol 1993; 231: 982-98.
25. Dellambra E, Golisano O, Bondanza S et al. Downregulation of 14-3-3σ prevents clonal evolution and leads to immortalization of primary human keratinocytes. J Cell Biol 2000; 149: 1117-29.
26. Vercoutter-Edouart AS, Lemoine J, Le Bourhis X et al. Proteomic analysis reveals that 14-3-3σ is down-regulated in human breast cancer cells. Cancer Res 2001; 61: 76-80.
27. Lehman U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002; 160: 605-12.
28. Loughran O, Malliri A, Owens D et al. Association of CDKN2A/ p16 with human head and neck keratinocyte replicative senescence: relationship of the dysfunction to immortality and neoplasia. Oncogene 1996; 13: 561-8.
29. Munro J, Stott FJ, Vousden KH, Peters G, Parkinson EK. Role of the alternative INK4A proteins in human keratinocyte senescence: evidence for the specific inactivation of p16 upon immortalization. Cancer Res 1999; 59: 2516-21.
30. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992; 79: 328-37.
31. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989; 8: 3905-10.
32. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989; 63: 4417-21.
33. Kurman RJ, Norris HJ, Wilkinson E. Tumors of the Cervix, Vagina and Vulva. Atlas of Tumor Pathology. 3rd Series, Fascicle 4. Washington, DC: Armed Forces Institute of Pathology, 1992; 77-95.
34. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18: 477-85.
35. Pugacheva EN, Ivanov AV, Kravchenko JE, Kopnin BP, Levine AJ, Chumakov PM. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 2002; 21: 4595-600.
36. Wang Q, Griffin H, Southern S et al. Functional analysis of the Human papillomavirus type 16, E1 = E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization. J Virol 2004; 78: 821-33.